Adirondack Theatre Fest names new artistic director
timesunion.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesunion.com Daily Mail and Mail on Sunday newspapers.
A closer look at the updated Provider Relief Fund guidance for healthcare providers
pbn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pbn.com Daily Mail and Mail on Sunday newspapers.
Print
As the coronavirus mutates, scientists are scrambling to modify vaccines to work better against specific viral variants.
Local biotech Inovio Pharmaceuticals is taking a different tack a single vaccine that could work across strains, maybe even against strains that are virtually unknown or don’t exist yet.
This week, the company reported early signs that its vaccine, INO-4802, has the potential to do exactly that. The vaccine, which uses DNA to teach the immune system to target the coronavirus, sparked immune responses to viral variants first identified in Brazil, the U.K. and South Africa, as well as the original Wuhan strain.
Inovio Pharmaceuticals (INO) Q1 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble.
Inovio Pharmaceuticals (NASDAQ: INO)
Operator
Good day, and welcome to the Inovio Pharmaceuticals first-quarter 2021 financial results conference call. [Operator instructions] Please note, this event is being recorded. I d now like to turn the conference over to Ben Matone, senior director of investor relations. Please go ahead.
Ben Matone
Senior Director of Investor Relations
Thank you, operator. Thank you for joining the Inovio first-quarter 2021 earnings conference call. Joining me on today s call are Dr. Joseph Kim, president and CEO; Mr.